Attached files

file filename
EX-32.1 - Vilacto Bio Inc.ex32-1.htm
EX-31 - Vilacto Bio Inc.ex31-2.htm
EX-31.1 - Vilacto Bio Inc.ex31-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10‑Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended December 31, 2016

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ______________

Commission File Number 000-55023

 
ZLATO INC.
(Exact name of registrant as specified in its charter)

Nevada
 
46-3883208
State or other jurisdiction of
 
(I.R.S. Employer
Incorporation or organization
 
Identification No.)

 Mlynska 28,  040 01 Kosice, Slovak Republic
 (Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 646-875-5747

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X]  No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [  ]
Accelerated filer [  ]
Non-accelerated filer [  ]
Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X]  No [  ]

Number of shares outstanding of the registrant’s class of common stock as February 15, 2017: 6,000,000

Authorized share capital of the registrant: 75,000,000 common shares, par value of $0.001

The Company recorded $nil sales revenue for the quarter ended December 31, 2016.
 

 
FORWARD-LOOKING STATEMENTS

 
THIS QUARTERLY REPORT ON FORM 10‑Q CONTAINS PREDICTIONS, PROJECTIONS AND OTHER STATEMENTS ABOUT THE FUTURE THAT ARE INTENDED TO BE “FORWARD‑LOOKING STATEMENTS” WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (COLLECTIVELY, “FORWARD‑LOOKING STATEMENTS”). FORWARD‑LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES. A NUMBER OF IMPORTANT FACTORS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD‑LOOKING STATEMENTS. IN ASSESSING FORWARD‑LOOKING STATEMENTS CONTAINED IN THIS QUARTERLY REPORT ON FORM 10‑Q, READERS ARE URGED TO READ CAREFULLY ALL CAUTIONARY STATEMENTS – INCLUDING THOSE CONTAINED IN OTHER SECTIONS OF THIS QUARTERLY REPORT ON FORM 10‑Q. AMONG SAID RISKS AND UNCERTAINTIES IS THE RISK THAT THE COMPANY WILL NOT SUCCESSFULLY EXECUTE ITS BUSINESS PLAN, THAT ITS MANAGEMENT IS ADEQUATE TO CARRY OUT ITS BUSINESS PLAN AND THAT THERE WILL  BE ADEQUATE CAPITAL OR THEY MAY BE UNSUCCESSUFL FOR TECHNICAL, ECONOMIC OR OTHER REASONS.

We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
 
PART I - FINANCIAL INFORMATION

 
ITEM 1.   FINANCIAL STATEMENTS

 
Page Number
   
Balance Sheets
3
Statements of Operations
4
Statements of Cash Flows
5
Notes to the Financial Statements
6
 
 
2

 
ZLATO INC.

BALANCE SHEETS


   
December 31,
2016
   
March 31,
2016
 
   
(unaudited)
       
ASSETS
           
             
Current assets
           
Cash and bank accounts
 
$
434
   
$
482
 
Prepaid rent
   
106
     
-
 
                 
Total current assets
   
540
     
482
 
                 
Total assets
 
$
540
   
$
482
 
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
               
                 
Current liabilities
               
Accounts payable
 
$
3,200
   
$
3,400
 
Due to director
   
32,608
     
21,586
 
                 
Total current liabilities
   
35,808
     
24,986
 
                 
Stockholders’ deficit
               
Authorized:
               
75,000,000 common shares
               
Par value $0.001
               
Issued and outstanding:
               
6,000,000 common shares
   
6,000
     
6,000
 
Additional paid-in capital
   
59,000
     
59,000
 
Accumulated deficit
   
(100,268
)
   
(89,504
)
                 
Total stockholders’ deficit
   
(35,268
)
   
(24,504
)
                 
Total liabilities and stockholders' deficit
 
$
540
   
$
482
 




The accompanying notes are an integral part of these financial statements.
 
 
3

 
ZLATO INC.

STATEMENTS OF OPERATIONS
(unaudited)


   
Three Months
Ended
December 31,
2016
   
Three Months
Ended
December 31,
2015
   
Nine Months
Ended
December 31,
2016
   
Nine Months
Ended
December 31,
2015
 
                         
REVENUE
 
$
-
   
$
-
   
$
-
   
$
-
 
                                 
OPERATING EXPENSES
                               
General & administrative
   
1,002
     
1,075
     
3,169
     
3,239
 
Professional fees
   
1,765
     
1,765
     
7,595
     
7,595
 
Loss before income taxes
   
(2,767
)
   
(2,840
)
   
(10,764
)
   
(10,834
)
                                 
Provision for income taxes
   
-
     
-
     
-
     
-
 
                                 
Net loss
 
$
(2,767
)
 
$
(2,840
)
 
$
(10,764
)
 
$
(10,834
)
                                 
Basic and diluted loss per common share (1)
                               
                                 
                                 
Weighted average number of common shares outstanding
   
6,000,000
     
6,000,000
     
6,000,000
     
6,000,000
 
 
_________________
(1) less than $0.01




The accompanying notes are an integral part of these financial statements.
 
 
4

 
ZLATO INC.

STATEMENTS OF CASH FLOWS
(unaudited)

   
Nine Months
Ended
December 31,
2016
   
Nine Months
Ended
December
31, 2015
 
OPERATING ACTIVITIES
           
Net loss for the period
 
$
(10,764
)
 
$
(10,834
)
Changes in operating assets and liabilities:
               
Prepaid rent
   
(106
)
   
(99
)
Accounts payable
   
(200
)
   
-
 
                 
Net cash used for operating activities
   
(11,070
)
   
(10,933
)
                 
FINANCING ACTIVITIES
               
Loan from director
   
11,022
     
11,146
 
                 
Net cash provided by financing activities
   
11,022
     
11,146
 
                 
(Decrease) increase in cash during the period
   
(48
)
   
213
 
                 
Cash, beginning of the period
   
482
     
-
 
                 
Cash, end of the period
 
$
434
   
$
213
 
                 
Supplemental disclosure with respect to cash flows:
               
Cash paid for income taxes
 
$
-
   
$
-
 
Cash paid for interest
 
$
-
   
$
-
 




The accompanying notes are an integral part of these financial statements.
 
 
5

 
ZLATO INC.

NOTES TO FINANCIAL STATEMENTS
December 31, 2016
(unaudited)


NOTE 1. GENERAL ORGANIZATION AND BUSINESS

The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013. The Company is devoting substantially all of its present efforts to establish a new business, and has had no revenues from operations to date.

Initial operations have included organization and capital formation. Management also has recently developed electronic medical record software for small to medium sized physician offices and clinics, and is planning to market it commercially when they can successfully raise the financing to do so.

NOTE  2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Basis
The accounting and reporting policies of the Company conform to U.S. generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for fair presentation have been included in the financial statements.

Basis of Presentation
The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars.  The Company has adopted a March 31 fiscal year end.

Dividends
The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown.

Cash
The Company’s cash consists of funds deposited with its lawyer into the law firm’s trust account.
 
 
6

 
ZLATO INC.

NOTES TO FINANCIAL STATEMENTS
December 31, 2016
(unaudited)


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Earnings per Share
The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. The Company has not issued any options or warrants or similar securities since inception.

Foreign Currency Translation
The Company has adopted the US dollar as its functional and reporting currency because most of its transactions are denominated in US currency.

Fair Value of Financial Instruments
The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts the Company could realize in a current market exchange.

Income Taxes
A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards.  Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
 
 
7

 
ZLATO INC.

NOTES TO FINANCIAL STATEMENTS
December 31, 2016
(unaudited)


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition
The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements
The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has net losses from the date of incorporation on February 25, 2013 to December 31, 2016 of $100,268. The ability of the Company to continue as a going concern is dependent upon the Company’s successful efforts to either generate revenues or raise sufficient capital for its business plans and then attain profitable operations. In response to these issues, management has planned the following actions:

-
The Company intends to fund its expenditures through loans or equity financing arrangements, which may be insufficient to fund its proposed development expenditures, working capital and other cash requirements through the next fiscal year.

-
Management is currently formulating plans to develop and sell electronic medical records software to generate future revenues. There can be no assurances, however, that management’s expectations of future revenues will be realized.
 
 
8

 
ZLATO INC.

NOTES TO FINANCIAL STATEMENTS
December 31, 2016
(unaudited)


NOTE 3. GOING CONCERN (continued)

Management estimates the minimum amount of additional funding necessary to enable the Company to carry out its intended business plan and remain viable for at least the twelve months following the date of the financial statements is approximately $50,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 4. STOCKHOLDERS’ EQUITY

Authorized

The Company is authorized to issue 75,000,000 shares of $0.001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company.

Issued and Outstanding

On February 25, 2013 (inception), the Company issued 5,000,000 shares of its common shares to its President, Secretary Treasurer and Director for cash of $.003 per share or$15,000 in aggregate. See Note 5. On September 30 and October 31, 2013 the Company accepted subscriptions under its registered offering for 1,000,000 shares of common stock for cash of $0.05 per share or aggregate proceeds of $50,000.

NOTE 5. RELATED PARTY TRANSACTIONS

The Company’s officer and director is involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

On February 25, 2013, the Company issued 5,000,000 shares of its common stock to its President, Secretary Treasurer and Director for cash of $15,000. See Note 4.

During the nine months ended December 31, 2016, the Director of the Company advanced $11,022 to the Company to pay expenses on behalf of the Company. Total advances to December 31, 2016 are $32,608. The advances bear no interest, are unsecured, and due on demand.
 
 
9

 
ZLATO INC.

NOTES TO FINANCIAL STATEMENTS
December 31, 2016
(unaudited)


NOTE 6.  INCOME TAXES

Net deferred tax assets are $0. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a 100% valuation allowance. Management believes it is likely that any deferred tax assets will not be realized.

   
March 31, 2016
   
March 31, 2015
 
             
Net loss before taxes
 
$
15,564
   
$
22,438
 
Statutory rate
   
35
%
   
35
%
                 
Computed expected tax recovery
   
5,447
     
7,853
 
Change in valuation allowance
   
(5,447
)
   
(7,853
)
                 
Income tax provision
  $
    $
 

The accumulated net losses to March 31, 2016 before taxes are $89,504, resulting in an aggregate deferred tax asset/recovery of $31,326. The Company has recorded a 100% valuation allowance due to the uncertainty of realization.

The Company’s aggregate net operating losses of $89,504 expire as follows:
 
March 31, 2033 -
 
$
555
 
March 31, 2034 -
   
50,947
 
March 31, 2035 -
   
22,438
 
March 31, 2036-
   
15,564
 
   
$
89,504
 
 
NOTE 7. SUBSEQUENT EVENTS

We have evaluated subsequent events through to the date of issuance of the financial statements, and did not have any material recognizable subsequent events after December 31, 2016.
 
 
10

 
ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with our financial statements and related notes appearing elsewhere in this Form 10-Q, together with the more detailed business information and the March 31, 2016 audited financial statements included in the Company's Annual Report on Form 10K (File No. 000-55023), as filed with the SEC on July 8, 2016. It also includes our detailed expenditures and plan of operations described herein. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute "forward-looking" statements.

General Overview

Our Company was incorporated in the State of Nevada on February 25, 2013 to engage in the development and sale of electronic medical record (“EMR”) software for small and medium sized physician offices and clinics. Our principal executive offices are located at Mlynska 28, 040 01 Kosice, Slovak Republic. Our phone number is (646) 875-5747. We are a development stage company and we have no subsidiaries. Our common shares are posted for trading on the OTC Markets under the symbol “ZFLO”.

We completed a registered offering and raised $50,000 in 2014, which we used to complete development of our basic EMR software and for the launch of our website. You can view the website and register to view and use our EMR software at www.zlatoinc.com.

Our basic EMR software collects and captures patient data electronically, and stores it in a format that enables efficient access and viewing, and distribution by printing or email. Our planned second phase product development will focus on interconnectivity of our EMR software with various third party vital signs monitors, such as blood pressure monitors or temperature monitors.

We currently have no revenues, no operating history, and no users or revenues for our software. We currently have little cash and a net working capital deficit. Therefore, our business will fail without immediate funding. We currently estimate that we will need an additional $10-15,000 just to maintain our corporate existence and meet our regulatory requirements over the next 12 months. Our director has indicated that she will fund our existing working capital deficit and minimum required expenditures the next quarter with a loan, but there are no arrangements thereafter.

We cannot guarantee we will be successful in doing so or with planned our business operations. Our business is subject to all of the risks inherent in the establishment of a new business enterprise and revenue generation from our basic EMR software product is dependent on additional financing as noted herein.

Going Concern

We have very limited operations and no revenues. We have incurred losses from operations since inception. No revenues are anticipated until we complete and successfully commercialize our planned EMR software. The ability of our Company to continue as a going concern is dependent on raising capital to fund our business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company's ability to continue as a going concern.

Our activities to date have been financed from the proceeds of share subscriptions and a loan from our director. From our inception to the present we have raised a total of $65,000 in gross proceeds from the issuance of our common stock. Our director also lent us $32,608 in aggregate for our operations. We require significant additional financing to develop our business. There is no guarantee that we will be able to raise any additional funds.
 
 
11

 
12 Month Plan of Operation

We cannot guarantee we will be successful in our business operations. Our business is subject to all of the risks inherent in the establishment of a new business enterprise and we are a number of months away from generating any revenue, if at all.

Our plan of operations over the next 12 month period is focused exclusively on raising additional capital for our survival and the commercial launch of our basic EMR software and development of an interoperability kit with third party monitoring equipment. We currently have little cash and a net working capital deficit. Therefore, our business will fail without immediate capital. We currently estimate that we will need an additional $10-15,000 just to maintain our corporate existence and meet our regulatory requirements over the next 12 months. Our director has indicated that she will only fund our existing working capital deficit and minimum required expenditures for the next quarter, and there are no arrangements thereafter. We currently estimate we will require an additional $200,000 for the commercial launch of our basic EMR software and another 8-10 months and $50,000 to develop the software development kit for interoperability with third parties. We do not have any arrangements in place for this additional financing.

Our commercial launch budget also includes approximately $20,000 for the development of an automated software deployment system which will enable us to either run the software for licensed users on our servers, or sell our software to clients via the internet. Fixes and updates should be easily deployed through this system, ensuring that all of our clients are running on the latest version. We also plan to hire a contract sales consultant at a monthly cost of $3,000. His or her initial responsibilities will focus on the selection of several beta test clients to test our software prior to commercial sale.

Ms. Gallovicova is responsible for all financing activities, and developing all job specifications for our third party contract software developers or firms. She will also be responsible for hiring the sales consultant, and will oversee the sales consultant in their role specifically as beta test subjects are selected and the marketing plan is developed.

Without additional financing on a timely basis, our business will fail.

Results of Operations

We incurred a loss of $2,767 and $2,840 for the three month periods ended December 31, 2016 and 2015 respectively. This three month loss includes $1,002 for general and administrative costs (2015 - $1,075) and $1,765 (2015 - $1,765) for professional fees.

We incurred a loss of $10,764 and $10,834 for the nine month periods ended December 31, 2016 and 2015 respectively. This nine month loss includes $3,169 for general and administrative costs (2015 - $3,239) and $7,595 (2015 - $7,595) for professional fees.

From inception on February 25, 2013 to December 31, 2016 we have incurred cumulative losses of $100,268. We believe we will continue to incur losses into the foreseeable future as we develop our business.

Revenues

We have not generated any revenues since February 25, 2013 (inception). Future revenue generation is dependent on obtaining the necessary financing to commercially launch our product.
 
 
12


Liquidity and Capital Resources

Historically, we have financed our cash flow and operations solely from the sale of $65,000 of common stock. Our director has also lent our Company $32,608 for working capital purposes. The loan does not bear interest and there are no specified repayment terms. She has indicated that she will not seek repayment until we have sufficient resources to do so. All of the funds we have raised were used for operating activities since our inception on February 25, 2013. As of December 31, 2016, our resultant cash balance was $434 and our net working capital deficit was $35,268.

We currently do not have the cash resources to continue with our business or maintain our existence. Our director has indicated that she will fund the estimated cash shortfall for the next quarter, but there are no further arrangements in place. We must also raise significant additional funding to launch our EMR product and develop interoperability.

These funds will have to be raised through equity financing, debt financing, or other sources, which may result in the dilution in the equity ownership of our shares. We will also need more funds if the costs of commercialization and further development are greater than we have budgeted. We will also require additional financing to sustain our business operations if we are ultimately not successful in earning revenues. We currently do not have any arrangements in place regarding our current offering or any subsequent offering for further financing and we may not be able to obtain financing when required. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

There are no assurances that we will be able to obtain further funds required for our continued operations. Even if additional financing is available, it may not be available on terms we find favorable. At this time, there are no anticipated sources of additional funds in place. Failure to secure the needed additional financing will have an adverse effect on our ability to remain in business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 3.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we are responsible for conducting an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the fiscal period covered by this report. Disclosure controls and procedures means that the material information required to be included in our Securities and Exchange Commission (“SEC”) reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, including any consolidating subsidiaries, and was made known to us by others within those entities, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of December 31, 2016.

Changes in internal control over financial reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
13

 
PART II – OTHER INFORMATION
 
 
ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.
 
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
 
None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.
 
ITEM 5. OTHER INFORMATION

None.
 
ITEM  6. EXHIBITS AND REPORTS ON FORM 8-K.
 
Pursuant to Rule 601 of Regulation SK, the following exhibits are included herein or incorporated by reference.

Exhibit
   
Number
 
Description
     
3.1
 
Articles of Incorporation*
3.2
 
By-laws*
31.1
 
Certification Pursuant to 18 U.S.C. ss. 1350, Section 302
31.2
 
Certification Pursuant to 18 U.S.C. ss. 1350, Section 302
32.1
 
Certification Pursuant to 18 U.S.C. ss.1350, Section 906
101
 
Interactive Data Files pursuant to Rule 405 of Regulation S-T
 
___________
* Incorporated by reference to our S-1 Registration Statement, File 333-188610, filed on May 15, 2013

Reports on Form 8-K

None.
 
 
14

 
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 17th February, 2017.

 
ZLATO INC.
   
     
Date: February 17, 2017
By: /s/ Dana Gallovicova
 
 
Name: Dana Gallovicova
 
Title: President, CEO, Secretary Treasurer
 
Principal Executive, Financial and Accounting Officer

15